Final answer:
The incorrect statement about anti-Fya and anti-Fyb is that they react well with enzyme-treated panel cells; these antibodies are clinically significant and can cause transfusion reactions and mild hemolytic disease of the newborn but do not typically improve in reaction with enzyme treatment.
Step-by-step explanation:
The statement that is NOT true concerning anti-Fya and anti-Fyb antibodies is that they react well with enzyme-treated panel cells. These antibodies are generally clinically significant because they can cause hemolytic transfusion reactions and are also associated with causing a mild hemolytic disease of the newborn. Anti-Fya and anti-Fyb do not typically react better with enzyme-treated cells; in fact, enzyme treatment can often weaken the reactions of these antibodies.
Anti-Fya and anti-Fyb can lead to complications in the case of incompatible blood transfusions beyond the commonly known ABO and Rh systems. For instance, in a transfusion scenario, if a recipient with anti-Fya or anti-Fyb antibodies is given donor blood with the corresponding antigens, this can lead to an immune response resulting in the destruction of the transfused red blood cells. Similarly, during pregnancy, if a fetus expresses the Fya or Fyb antigen that the mother lacks, and she has developed antibodies, this can lead to a condition similar to erythroblastosis fetalis, where the maternal antibodies cross the placenta and cause hemolysis in the fetal red cells.